ED Coding & Reimbursement Alert - 2003 Issue 8
Reimbursement: GAO TARGETS NEW AWP PAYMENT HEMORRHAGE
Subscribe or sign in to view the full article.
Article Overview
This short reimbursement news item discusses a GAO report on Medicare payment for blood clotting factor and the broader issue of drug pricing based on average wholesale price. It is relevant to readers tracking Medicare payment policy, biologicals, hemophilia treatment services, and the financial impact on providers. The article also notes the GAO’s recommendation that CMS consider separate payment for delivery-related costs if reimbursement is reduced.
Why This Topic Matters
It helps billing, reimbursement, and compliance professionals understand a federal review of Medicare payment methodology for a high-cost biological and the possible implications for provider costs and payment policy.
What You Will Learn
- Why the article discusses Medicare reimbursement concerns for a blood clotting factor biological
- How the GAO report frames payment methodology and provider acquisition cost issues
- What general payment-policy concern is raised for providers who deliver clotting factor to Medicare beneficiaries
- How the report relates to broader discussions about drug and biological payment policy
Who Should Read This
- Medical coders
- Reimbursement specialists
- Billing staff
- Compliance teams
- Hemophilia treatment center administrators
- Home infusion or home care billing professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com